ESPE Abstracts (2014) 82 P-D-2-2-522

ESPE2014 Poster Category 2 Pituitary (1) (8 abstracts)

Treatment Options in a 14-Year-Old Boy with an Atypic Cabergolin-Resistant Macroprolactinoma with Somatostatin Receptor 2 Expression and an Increased Proliferation Rate

Angela Huebner a , Felix Reschke a , Gabriele Hahn b , Thomas Pinzer c , Matthias Meinhardt d , Anke Pyper a , Salvatore Cannavò e , Gunter Stalla f & Lorenz C. Hofbauer g

aDepartment of Paediatrics, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; bDivision of Paediatric Radiology, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; cDepartment of Neurosurgery, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; dDepartment of Neuropathology, Institute for Pathology, Universitätsklinikum Carl Gustav Carus, Technische Univerität Dresden, Dresden, Germany; eSection of Endocrinology, Department of Medicine and Pharmacology, University of Messina, Messina, Italy; fDepartment of Internal Medicine, Endocrinology and Clinical Chemistry, Max Planck Institute for Psychiatry, Munich, Germany; gDivision of Endocrinology, Diabetes and Bone Diseases, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Background: Macroprolactinomas in children below 10 years of age are rare. Usually prolactinomas respond well to dopamine agonists so that neurosurgical resection is rarely necessary. For non-responders to dopamine agonist therapy other extended treatment options have to be considered.

Clinical case: We report a 14-year-old boy who presented at the age of 11 years with headaches for 5 years and progressive bilateral vision problems. The diagnosis of a macroprolactinoma was made on the basis of elevated prolactin levels of 6727 mU/l (NR 86–324) and on typical MRI features with a large intra- and suprasellar mass infiltrating the clivus and both sinus cavernosus and displacing the chiasm. Cabergoline treatment was started immediately with increasing doses of 0.5–7 mg/week resulting in a transient fall of prolactin levels to 2000 mU/l with no reduction of tumour mass after 10 weeks of treatment. In order to prevent bilateral blindness, partial resection of the tumour was performed.

Results: Histopathology confirmed a prolactinoma with an increased proliferation rate (Ki 67) of 5% (focally up to 10%) as well as p53 (10%), and a strong somatostatin receptor 2 expression. Metastases were not found and MEN1 and AIP gene sequencing was normal. Postoperatively, cabergoline and quinagolide treatment were ineffective. The tumour partially responded to octreotide up to 30 mg/month, however prolactin levels are rising and tumour size increased again after 13 months. Repeated transsphenoidal surgery will be performed followed by either temozolamide treatment or radiotherapy.

Conclusion: Atypic macroprolactinomas with a high proliferation index starting at an age of about 6 years as in our case are extremely rare. If dopamine agonist therapy fails and the tumour cells express somatostatin receptor 2 octreotide could be one treatment option although there is little experience for this age group. Final treatment strategies may include stereotactic radiation and temozolamide.

Article tools

My recent searches

No recent searches.